The second set of biomarkers is related to neuronal injury and includes the presence of phosphorylated-tau in the CSF, volumetric measurements or visual assessments of hippocampal volume or medial temporal lobe atrophy, the rate of brain atrophy, fluorodeoxyglucose-18 (FDG)-PET imaging, and single-photon emission computed tomography (SPECT) perfusion imaging. The gene discussed is MAPT; the disease is Brain atrophy.